Category Archives: MS Treatment

LA JOLLA, Calif. Scientists have discovered a potential medical breakthrough in the treatment of multiple sclerosis. Researchers from Sanford Burnham Prebys unveiled a remarkable molecular connection between vitamin B12 and MS, occurring within astrocytes, non-neuronal glial cells in the brain Continue reading →

Similar to previously published data, new findings from a population-based cohort study of Italian adults with multiple sclerosis (MS) showed that a high level of adherence to disease-modifying therapies (DMTs) is associated with a lower risk of moderate or severe relapse. Above all, these data reinforce the importance of the choice of which drug to start MS treatment Continue reading →

Sarah Anderson, PharmD, NBC-HWC ACCESS TO AFFORDABLE, appropriate, high-quality health care is essential for people with MS [multiple sclerosis] to live their best lives, according to the National MS Society.1 Generics and biosimilars have the potential to contribute to the realization of this principle. Although there are known obstacles that play a role in the use of generics and biosimilars in the United States, generics and biosimilars are important treatment options because they have no clinically meaningful differences from their reference medicines. Continue reading →

Regulators in Britain on Thursday approved the first treatment derived from CRISPR, the revolutionary gene-editing method. Called Casgevy, the treatment is intended to cure sickle-cell disease and a related condition, beta thalassemia. The manufacturers, Vertex Pharmaceuticals, based in Boston, and CRISPR Therapeutics, based in Switzerland, say about 2,000 patients in Britain with sickle-cell disease or beta thalassemia are expected to be eligible for the treatment. Continue reading →

The U.S. Food and Drug Administration is reviewing a cutting-edge therapy called exa-cel that could potentially cure people of sickle cell disease, a painful and deadly disease with no universally successful treatment. Continue reading →

Study design and oversight The main goal of the TAMARIN study (EudraCT 2015-005497-38) was to obtain preliminary information on the safety and therapeutic activity of tamoxifen in MPN. TAMARIN is an investigator-driven Aherns design Phase II multicenter study approved by NHS Health Research Authority (IRAS 201126). The study was conducted in accordance with the Declaration of Helsinki and UK regulations (The Medicines for Human Use (Clinical Trials) Regulations 2004). Continue reading →

Sponsored in part by Daiichi Sankyo. Continue reading →

Microbiota associations with extended antibiotic exposure We first assessed HAD gut microbiota structure and diversity with respect to antibiotic treatment using alpha and beta diversity measures and analysis of compositions of microbiomes (ANCOM) differential abundance analysis. Antibiotic-associated diarrhoeal (+AAD) patients comprised 82.2% (139/169) of the cohort (Table1) and were associated with 56 unique combinations of antibiotic classes before specimen collection (Supplementary Table1), rendering analysis by antibiotic class unfeasible Continue reading →

Kenneth L. Continue reading →

November 22, 2023 GE HealthCare is preparing to showcase its Artificial Intelligence (AI)-enabled solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America, RSNA 2023, being held Nov. 26-30 in Chicago, IL. In a statement issued by the company summarizing the range of products to be showcased during the meeting, the company noted findings from a report by RBC Capital Markets that approximately 30% of the worlds data is generated by healthcare (1), and that 97% of data produced by hospitals remains unused (2). Continue reading →